Nuwellis (NASDAQ:NUWE) Posts Earnings Results, Misses Expectations By $2.84 EPS

Nuwellis (NASDAQ:NUWE) issued its earnings results on Thursday. The company reported ($26.64) earnings per share for the quarter, missing the consensus estimate of ($23.80) by ($2.84), Zacks reports. Nuwellis had a negative net margin of 214.90% and a negative return on equity of 32,351.83%. The firm had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.42 million.

Here are the key takeaways from Nuwellis’ conference call:

• Second-quarter revenue rose 14% year over year to $1.97 million, with U.S. revenue up 17%; first-half revenue increased 20% to $4.37 million, driven by stronger U.S. growth and increased console placements.
• Gross margin improved substantially to 76% from 56% a year ago, benefiting from higher average selling prices, favorable product mix, and the transition to contract manufacturing.
• Nuwellis sold nine consoles in the quarter and 24 in the first half, versus five in the first half of 2025, while expanding pediatric programs and targeting greater recurring circuit utilization in pediatrics and adult critical care.
• The company plans to submit an FDA application in the fourth quarter to expand Aquadex use to patients weighing at least 5 kilograms, while Clarity Prime is targeted for launch in 2027 and new critical-care capabilities remain under development.
• Despite the improved gross margin, Nuwellis reported a $4.8 million net loss and had only $3.9 million in cash at quarter-end; subsequent financings and warrant exercises raised approximately $6.7 million but may increase dilution.

Nuwellis Stock Performance

NUWE traded down $0.11 during trading on Thursday, hitting $1.30. The stock had a trading volume of 683,993 shares, compared to its average volume of 8,940,867. The firm has a market capitalization of $2.42 million, a P/E ratio of -0.00 and a beta of 0.31. Nuwellis has a twelve month low of $1.25 and a twelve month high of $235.20. The company’s 50-day moving average price is $3.17 and its 200 day moving average price is $34.52.

Analyst Ratings Changes

Several research firms have commented on NUWE. Wall Street Zen raised Nuwellis to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.